These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 11683962)
1. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Lin F; Fukuoka Y; Spicer A; Ohta R; Okada N; Harris CL; Emancipator SN; Medof ME Immunology; 2001 Oct; 104(2):215-25. PubMed ID: 11683962 [TBL] [Abstract][Full Text] [Related]
2. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961 [TBL] [Abstract][Full Text] [Related]
3. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lin F; Emancipator SN; Salant DJ; Medof ME Lab Invest; 2002 May; 82(5):563-9. PubMed ID: 12003997 [TBL] [Abstract][Full Text] [Related]
4. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes. Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614 [TBL] [Abstract][Full Text] [Related]
5. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition. Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240 [TBL] [Abstract][Full Text] [Related]
6. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624 [TBL] [Abstract][Full Text] [Related]
7. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor. Miwa T; Okada N; Okada H Immunogenetics; 2000 Feb; 51(2):129-37. PubMed ID: 10663575 [TBL] [Abstract][Full Text] [Related]
8. Tissue distribution of the rat analogue of decay-accelerating factor. Spiller OB; Hanna SM; Morgan BP Immunology; 1999 Jul; 97(3):374-84. PubMed ID: 10447757 [TBL] [Abstract][Full Text] [Related]
9. Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis. Li Q; Huang D; Nacion K; Bu H; Lin F Mol Immunol; 2009 Sep; 46(15):2885-91. PubMed ID: 19660813 [TBL] [Abstract][Full Text] [Related]
10. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. Lin F; Salant DJ; Meyerson H; Emancipator S; Morgan BP; Medof ME J Immunol; 2004 Feb; 172(4):2636-42. PubMed ID: 14764738 [TBL] [Abstract][Full Text] [Related]
11. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1. Cauvi DM; Cauvi G; Pollard KM J Immunol; 2006 Sep; 177(6):3837-47. PubMed ID: 16951346 [TBL] [Abstract][Full Text] [Related]
12. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Miwa T; Zhou L; Hilliard B; Molina H; Song WC Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227 [TBL] [Abstract][Full Text] [Related]
13. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684 [TBL] [Abstract][Full Text] [Related]
15. Overexpression of Decay Accelerating Factor Mitigates Fibrotic Responses to Lung Injury. Vittal R; Fisher AJ; Thompson EL; Cipolla EM; Gu H; Mickler EA; Varre A; Agarwal M; Kim KK; Vasko MR; Moore BB; Lama VN Am J Respir Cell Mol Biol; 2022 Oct; 67(4):459-470. PubMed ID: 35895592 [TBL] [Abstract][Full Text] [Related]
16. Differential expression of decay-accelerating factor isoforms in the digestive tract of guinea pig. Mizoshita T; Joh T; Oshima T; Yamada T; Ohara H; Nomura T; Okada N; Itoh M Life Sci; 2002 Jan; 70(8):867-76. PubMed ID: 11853224 [TBL] [Abstract][Full Text] [Related]
17. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice. Fang C; Miwa T; Shen H; Song WC J Immunol; 2007 Sep; 179(5):3178-86. PubMed ID: 17709533 [TBL] [Abstract][Full Text] [Related]
18. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Qian YM; Haino M; Kelly K; Song WC Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231 [TBL] [Abstract][Full Text] [Related]
19. Deletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attack. Barata L; Miwa T; Sato S; Kim D; Mohammed I; Song WC J Immunol; 2013 Mar; 190(6):2886-95. PubMed ID: 23390291 [TBL] [Abstract][Full Text] [Related]
20. Complement-mediated clearance of erythrocytes: mechanism and delineation of the regulatory roles of Crry and DAF. Decay-accelerating factor. Molina H; Miwa T; Zhou L; Hilliard B; Mastellos D; Maldonado MA; Lambris JD; Song WC Blood; 2002 Dec; 100(13):4544-9. PubMed ID: 12393518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]